|
2
|
Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, Anckarsäter R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, Johnsen L, Fladby T, Tarkowski A, Trysberg E, Wallin A, Anckarsäter H, Lycke J, Andersen O, Simon AJ, Blennow K, Zetterberg H. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 2009; 15:448-54. [DOI: 10.1177/1352458508100031] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Cell and animal experiments have shown that β-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination. Objective Here, we assess the association of cerebrospinal fluid (CSF) BACE1 activity with multiple sclerosis (MS). Methods BACE1 activity and levels of secreted amyloid precursor protein (APP) and amyloid-β (Aβ) isoforms were analyzed in CSF from 100 patients with MS and 114 neurologically healthy controls. Patients with systemic lupus erythematosus (SLE), 26 with and 41 without cerebral engagement, were also included to enable comparisons with regards to another autoimmune disease. A subset of patients with MS and controls underwent a second lumbar puncture after 10 years. Results MS patients had lower CSF BACE1 activity than controls ( P = 0.03) and patients with cerebral SLE ( P < 0.001). Patients with cerebral SLE had higher BACE1 activity than any other group ( P < 0.05 for all comparisons). BACE1 activity correlated with the different amyloid markers in all study groups. BACE1 activity decreased over 10 years in the MS group ( P = 0.039) and correlated weakly with clinical disease severity scores in an inverse manner. Conclusions These results suggest an involvement of BACE1 in the MS disease process.
Collapse
Affiliation(s)
- N Mattsson
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
| | - M Axelsson
- Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - S Haghighi
- Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - C Malmeström
- Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - G Wu
- Alzheimer’s Research, Merck Research Laboratories, West Point, PA, USA
| | - R Anckarsäter
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; Department of Anaesthesiology and Intensive Care, Kungälv Hospital, Kungälv, Sweden
| | | | - U Andreasson
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
| | - S Fredrikson
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - A Gundersen
- University of Oslo, Department of Neurology at Akershus University Hospital, Norway
| | - L Johnsen
- University of Oslo, Department of Neurology at Akershus University Hospital, Norway
| | - T Fladby
- University of Oslo, Department of Neurology at Akershus University Hospital, Norway
| | - A Tarkowski
- Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - E Trysberg
- Department of Rheumatology, Karolinska Institutet, Stockholm, Sweden
| | - A Wallin
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
| | - H Anckarsäter
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; Institute for Clinical Sciences, Malmö University Hospital, Lund University, Sweden
| | - J Lycke
- Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - O Andersen
- Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - AJ Simon
- Alzheimer’s Research, Merck Research Laboratories, West Point, PA, USA
| | - K Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
| | - H Zetterberg
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
| |
Collapse
|